April 8 (Reuters) - AbbVie (ABBV.N), opens new tab has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for a drug discount program. Under ‌the 340B program, ...

Shares of AbbVie Inc. (ABBV) are down approximately 10% since my October 2025 update, in which I outlined the strong commercial progress and the company’s emerging efforts in the obesity market with ...

AbbVie has filed a lawsuit challenging federal guidance on how “patient” is defined under the 340B program, according to an April 8 press release. The company said the current definition, based on ...

JPMorgan maintains its Overweight rating and $260 price target on AbbVie (ABBV), calling the pullback a buying opportunity as the firm sees upside to consensus estimates backed by strong Skyrizi and ...

AbbVie (ABBV) and Roche’s (RHHBY) Genentech unit have become the latest drugmakers to offer their medicines on TrumpRx, a government-run direct-to-consumer platform launched earlier this year, ...

Two more drug-making giants will officially start selling popular commercial medications on the White House's discounted pharmaceutical site as soon as Monday, CBS News exclusively learned. American ...

AbbVie's growth rate has been impressive given the headwinds it has faced. This year, it's forecasting a significant increase in its earnings. AbbVie has faced some significant challenges in recent ...

Shares of AbbVie Inc. ABBV rose 2.05% to $217.49 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.91% to 6,528.52 and the ...

AbbVie has increased its dividend by more than 330% since 2013. It has a robust pipeline of drugs in development and growing revenue, too. One reason to consider investing in AbbVie is that it's a ...

AbbVie (ABBV) generated $17.82B in free cash flow against $11.66B in dividend payments (1.53x coverage), with Skyrizi reaching $5.01B in Q4 revenue, up 32.5% year-over-year. Pfizer (PFE) reported ...

Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March. J&J spent $50.3 million on TV ads for ...